Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Neutralizing Norovirus: NIAID Monoclonal Antibodies Licensing Opportunity

by Global Biodefense Staff
November 25, 2020
Neutralizing Norovirus: NIAID Monoclonal Antibodies Licensing Opportunity

Credit: Shutterstock

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a therapeutic or a diagnostic for norovirus infections.

The available technology relates to chimpanzee-human chimeric monoclonal antibodies that specifically bind to norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against norovirus and may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals, or to be used to develop a diagnostic for detection of norovirus infections.

Read more about this exciting collaboration opportunity: https://lnkd.in/effyMEB or contact Peter Soukas, J.D., 301-496-2644; peter.soukas@nih.gov

Tags: Editor PickNIAIDNorovirusRapid DiagnosticsTech Transfer

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
research team gathers in front of a window
CBRNE

UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism

August 24, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Supplemental Funding for Research at NIAID Regional Biocontainment Laboratories
Biosecurity

Supplemental Funding for Research at NIAID Regional Biocontainment Laboratories

May 5, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC